Sangamo Therapeutics Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Sep '25 Sep 30, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020
Revenue	32.88	57.8	176.23	111.3	110.7	118.19
Revenue Growth (YoY)	-37.13%	-67.20%	58.34%	0.54%	-6.34%	15.39%
Cost of Revenue	104.91	111.52	230.46	249.9	230.82	180.65
Gross Profit	-72.03	-53.72	-54.23	-138.6	-120.12	-62.46
Selling, General & Admin	36.89	44.63	60.07	62.68	63.22	67.1
Operating Expenses	36.89	44.63	60.07	62.68	63.22	67.1
Operating Income	-108.93	-98.35	-114.29	-201.28	-183.34	-129.55
Interest & Investment Income	8.04	8.2	8.25	6.43	5.35	8.78
Currency Exchange Gain (Loss)	-6.34	-2.94	2.85	-	-	-
EBT Excluding Unusual Items	-109.85	-93.09	-103.19	-194.85	-177.99	-120.78
Merger & Restructuring Charges	-0.1	-0.1	-4.7	-	-	-
Impairment of Goodwill	-	-	-38.14	-	-	-
Gain (Loss) on Sale of Investments	0.6	0.6	-	-	-	-
Asset Writedown	-	-5.52	-116.88	-	-	-
Other Unusual Items	-	-	-	3	-	-
Pretax Income	-109.35	-98.11	-262.9	-191.85	-177.99	-120.78
Income Tax Expense	-0.44	-0.17	-5.07	0.43	0.31	0.35
Earnings From Continuing Operations	-108.91	-97.94	-257.83	-192.28	-178.3	-121.12
Minority Interest in Earnings	-	-	-	-	0.01	0.13
Net Income	-108.91	-97.94	-257.83	-192.28	-178.29	-121
Net Income to Common	-108.91	-97.94	-257.83	-192.28	-178.29	-121
Shares Outstanding (Basic)	248	202	174	154	145	134
Shares Outstanding (Diluted)	248	202	174	154	145	134
Shares Change (YoY)	28.22%	15.62%	13.02%	6.76%	7.53%	19.92%
EPS (Basic)	-0.44	-0.49	-1.48	-1.25	-1.23	-0.90
EPS (Diluted)	-0.44	-0.49	-1.48	-1.25	-1.23	-0.90
Free Cash Flow	-76.4	-67.41	-246	-243.8	-256.53	155.16
Free Cash Flow Per Share	-0.31	-0.33	-1.41	-1.58	-1.77	1.15
Gross Margin	-219.11%	-92.94%	-30.77%	-124.53%	-108.51%	-52.84%
Operating Margin	-331.33%	-170.15%	-64.85%	-180.85%	-165.62%	-109.61%
Profit Margin	-331.28%	-169.45%	-146.30%	-172.76%	-161.05%	-102.37%
Free Cash Flow Margin	-232.38%	-116.62%	-139.59%	-219.05%	-231.73%	131.28%
EBITDA	-104.68	-93.24	-99.23	-189.17	-173.9	-123.87
EBITDA Margin	-	-161.32%	-56.31%	-169.97%	-157.09%	-104.80%
D&A For EBITDA	4.24	5.11	15.07	12.11	9.44	5.68
EBIT	-108.93	-98.35	-114.29	-201.28	-183.34	-129.55
EBIT Margin	-	-170.15%	-64.85%	-180.85%	-165.61%	-109.61%

Source: S&P Global Market Intelligence. Standard template. Financial Sources.